ArticlePloS one2025
Integrating post-validation surveillance of lymphatic filariasis with the WHO STEPwise approach to non-communicable disease risk factor surveillance in Niue, a study protocol.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Integrated surveillance for lymphatic filariasis and other infectious diseases with a nationwide non-communicable disease STEPwise survey in the small Pacific Island Nation of Niue, 2025.Scientific reports · 2026Article
- Comparison of an integrated versus stand-alone approach to post-validation surveillance for lymphatic filariasis in Niue: a micro-costing study, 2025.Journal of global health · 2026Article
- Challenges to 'Last Mile' Surveillance: Result of Programmatic Review of Integrated Skin NTDs Surveillance in Three Indonesian Districts.Tropical medicine and infectious disease · 2026Article
- Enablers of Post-Validation Surveillance for Lymphatic Filariasis in the Pacific Islands: A Nominal Group Technique and Expert Elicitation.Tropical medicine and infectious disease · 2026Article
- Integrated Approaches to Surveillance of Lymphatic Filariasis and Other Infectious Diseases in the Pacific Islands.Tropical medicine and infectious disease · 2026Article
- Article
- Global Lymphatic Filariasis Post-Validation Surveillance Activities in 2025: A Scoping Review.Tropical medicine and infectious disease · 2026Review
- Barriers and Facilitators to Implementing Post-Validation Surveillance of Lymphatic Filariasis in Pacific Island Countries and Territories: A Conceptual Framework Developed from Qualitative Data.Tropical medicine and infectious disease · 2026Article
- Reactive case detection can improve the efficiency of lymphatic filariasis surveillance compared to random sampling, Samoa 2023.PLoS neglected tropical diseases · 2025Article
- Persistent lymphatic filariasis transmission seven years after validation of elimination as a public health problem: a cross-sectional study in Tonga.The Lancet regional health. Western Pacific · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLymphatic filariasis (LF), a mosquito-borne parasitic disease caused by three species of filarial worms, was first detected in Niue, a small Pacific Island nation of approximately 1,600 people, in 1954. After extensive efforts involving multiple rounds of Mass Drug Administration, Niue was validated by the World Health Organization (WHO) as having e4liminated LF as a public health problem in 2016. However, no surveillance has been conducted since validation to confirm infection rates have remained below WHO's elimination threshold. WHO has encouraged an integrated approach to disease surveillance and integrating LF post-validation surveillance (PVS) with existing surveys is an anticipated recommendation of the upcoming WHO LF-PVS guidelines. This paper describes a protocol for the implementation of an integrated approach to LF-PVS in Niue as cost-efficient and operationally feasible means of monitoring the disease in the population.
methodsThe LF-PVS will be implemented as part of a planned national population-based WHO STEPwise approach to non-communicable disease (NCD) risk factor surveillance (STEPS) in Niue. Integration between the LF-PVS and STEPS will occur at multiple points, including during pre-survey community awareness raising and engagement, when obtaining informed consent, during the collection of demographics, risk factor, and location data, and when collecting finger-prick blood samples (for glucose as part of the STEPS survey and LF as part of the LF-PVS). The primary outcome measure for LF transmission will be antigen positivity. Microfilaria slides will be prepared for any antigen-positive cases. Dried blood spots will be prepared for all participants for Multiplex Bead Assays-based analysis to detect anti-filarial antibodies. We estimate a total sample size of 1,062 participants aged 15-69, representing approximately 66% of the population.
conclusionsThe results of this study will provide insight into the status of LF in Niue and evaluate the advantages, challenges, and opportunities offered by integrated approaches to disease surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.